

1 **Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada**

2

3 David N. Fisman MD MPH and Ashleigh R. Tuite PhD MPH

4

5 Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

6

7

8 **Address reprint requests and correspondence to:**

9 David Fisman, MD MPH FRCP(C)

10 Room 686, 155 College Street, Toronto, Ontario, M5T 3M7

11 Email: david.fisman@utoronto.ca

12

13 Funding statement: The research was supported by a grant to DNF from the Canadians Institutes
14 for Health Research (2019 COVID-19 rapid researching funding OV4-170360).

15

16 Declaration of competing interests: Dr. Fisman has served on advisory boards related to
17 influenza and SARS-CoV-2 vaccines for Seqirus, Pfizer, Astrazeneca and Sanofi-Pasteur
18 Vaccines, and has served as a legal expert on issues related to COVID-19 epidemiology for the
19 Elementary Teachers Federation of Ontario and the Registered Nurses Association of Ontario.

20

21 **Abstract**

22

23 **Background:** The period from February to June 2021 was one during which initial wild-type
24 SARS-CoV-2 strains were supplanted in Ontario, Canada, first by variants of concern (VOC)
25 with the N501Y mutation (Alpha/B.1.1.17, Beta/B.1.351 and Gamma/P.1 variants), and then by
26 the Delta/B.1.617 variant. The increased transmissibility of these VOCs has been documented
27 but data for increased virulence is limited. We used Ontario's COVID-19 case data to evaluate
28 the virulence of these VOCs compared to non-VOC SARS-CoV-2 infections, as measured by
29 risk of hospitalization, intensive care unit (ICU) admission, and death.

30 **Methods:** We created a retrospective cohort of people in Ontario testing positive for SARS-
31 CoV-2 and screened for VOCs, with dates of test report between February 7 and June 27, 2021
32 (n=212,332). We constructed mixed effects logistic regression models with hospitalization, ICU
33 admission, and death as outcome variables. Models were adjusted for age, sex, time, vaccination
34 status, comorbidities, and pregnancy status. Health units were included as random intercepts.

35 **Results:** Compared to non-VOC SARS-CoV-2 strains, the adjusted elevation in risk associated
36 with N501Y-positive variants was 52% (43-62%) for hospitalization; 89% (67-116%) for ICU
37 admission; and 51% (30-74%) for death. Increases with Delta variant were more pronounced:
38 108% (80-138%) for hospitalization; 234% (164-331%) for ICU admission; and 132% (47-
39 230%) for death.

40 **Interpretation:** The progressive increase in transmissibility and virulence of SARS-CoV-2
41 VOCs will result in a significantly larger, and more deadly, pandemic than would have occurred
42 in the absence of VOC emergence.

43

44 **Introduction**

45

46 Novel SARS-CoV-2 variants of concern (VOC), including viral lineages carrying the N501Y
47 and/or E484K mutations (Alpha/B.1.1.7, Beta/B.1.351 and Gamma /P.1, were first identified in
48 Ontario, Canada in December 2020 (1). While infection with such lineages was initially
49 uncommon, these VOCs outcompeted earlier SARS-CoV-2 lineages in Ontario, and as of late
50 April 2021 comprised almost all new infections in Ontario, with Alpha being the most prevalent
51 lineage(1). In April 2021, the B.1.617.2 variant, now known as “Delta” under revised World
52 Health Organization nomenclature, emerged in the province and outcompeted earlier VOCs,
53 representing the majority of infections in the province as of July 2021 (2, 3).

54

55 This serial replacement by emerging variants reflects progressively higher effective reproduction
56 numbers which allow novel variants to outcompete previously dominant strains in the face of
57 identical disease control interventions (4-6). However, VOCs are also concerning because of an
58 apparent increase in virulence, with increased risk of hospitalization, intensive care unit
59 admission and death, after adjustment for age and other predictive factors (7-10). Although the
60 increased virulence of strains with the N501Y mutation relative to strains which lack this
61 mutation has been described (7-9), only limited information is available on the virulence of
62 infection with the Delta variant, relative to earlier N501Y-positive VOCs (i.e., Alpha, Beta, and
63 Gamma) (10). Our objectives were (i) to use Ontario’s COVID-19 case data to evaluate the
64 virulence of N501Y-positive variants relative to earlier SARS-CoV-2 lineages; and (ii) to
65 evaluate the virulence of the Delta variant of SARS-CoV-2 relative to N501Y-positive VOCs.

66

67

68 **Methods**

69

70 *Data Sources*

71 We created a retrospective cohort of people in Ontario testing positive for SARS-CoV-2 and
72 screened for variants of concern, with dates of test report between February 7 and June 22, 2021.
73 Case information was extracted from the Ontario provincial Case and Contact Management
74 (CCM) database as described elsewhere (11). Although VOC cases were identified in Ontario
75 beginning in December 2020, systematic screening was not implemented until February 2021,
76 after which time all COVID-19 PCR positive specimens with a cycle threshold (Ct) value ≤ 35
77 were screened for the N501Y mutation using a single nucleotide polymorphism real-time PCR
78 assay developed at the Public Health Ontario Laboratory. On March 22, 2021, Ontario initiated
79 universal screening for N501Y and E484K mutations using a multiplex real-time PCR assay on
80 all specimens testing positive for SARS-CoV-2 with a Ct value ≤ 35 . Whole genome sequencing
81 (WGS) was performed on a 5% sample of specimens regardless of the presence of mutations.
82 Initially all specimens with the N501Y and/or E484K mutation and Ct value ≤ 30 were
83 sequenced; however, as of June 2021 routine WGS was no longer performed on specimens
84 without E484K, under the presumption that such specimens were of the Alpha lineage. By late
85 April 2021, more than 90% of infections in Ontario were screen positive for N501Y(Figure 1);
86 subsequently, N501Y mutations became less common, and N501Y-negative specimens subjected
87 to WGS were demonstrated to be predominantly Delta variant, with Delta representing $> 60\%$ of
88 new infections in Ontario on July 1, 2021 (2, 3). Analyses were restricted to individuals whose
89 viral isolate had been screened for a VOC. Cases were classified as N501Y-positive (screening
90 positive for N501Y or identified as Alpha, Beta, or Gamma by WGS), probable Delta variant
91 (identified by WGS at any point in time or negative for N501Y and any other mutations from

92 May 1, 2021 onward), or not VOC (all N501Y negative cases between February 7 and April
93 30, 2021 and all non-Delta cases testing positive for a mutation other than N501Y regardless of
94 date). Individuals for whom VOC screening information was not available (N = 31,464), or for
95 whom screening could not be completed (N = 13,579) were excluded from the analysis. We
96 further restricted our analysis to individuals without a record of long-term care residence, as the
97 epidemiology and severity of SARS-CoV-2 infection in long-term care home residents have been
98 distinct in Ontario (12, 13). The dataset was extracted on July 13, 2021, with the most recent test
99 report date of July 12, 2021. We included cases with a test report date at least 14 days prior (June
100 27, 2021) to account for delays between testing and occurrence of hospitalization, intensive care
101 unit (ICU) admission, and death. Vaccination data for cases, including dates of administration of
102 first and second doses of approved SARS-CoV-2 vaccines (where relevant) were obtained from
103 COVaxON, a centralized COVID-19 vaccine information system for the province. Individuals
104 were categorized as fully vaccinated if the case episode date occurred 7 or more days after
105 receipt of the second dose; partially vaccinated if the case episode date occurred 14 days or more
106 after receipt of the first dose but less than 7 days after receipt of the second dose; and
107 unvaccinated otherwise.

108 *Analysis*

109 We constructed mixed effects logistic regression models with hospitalization, ICU admission,
110 and death as dependent variables. Models were adjusted for age (by 10-year increments), male
111 sex, time (modeled as a week-on-week linear trend), vaccination status, and any documented
112 major comorbidity (including asthma, COPD, hematological disease, liver disease, cardiac
113 disease, diabetes, immune compromise, renal disease, neurological disease, malignancy, or
114 obesity). Hospitalization and ICU models were also adjusted for pregnancy, which was excluded

115 from models evaluating death due to the rarity of fatalities among pregnant individuals. Due to
116 geographic variation in prevalence of variants, health units were included as random intercepts.
117 Confidence intervals were calculated by parametric bootstrap, assuming fixed effects. As
118 hospitalization, ICU admission and death were fortunately relative rare among cases, we
119 considered odds ratios to approximate relative risks under the “rare disease assumption” (14). In
120 a separate analysis, we explored the apparent linear increase in virulence from non-VOC to
121 N501Y-positive VOC to Delta variant by modeling VOC status of cases as a 3-level ordinal
122 variable. We conducted all analyses in R version 4.1.0 using the lme4 and broom.mixed
123 packages (15-17). The study was conducted in accordance with the STROBE guidelines for
124 observational research (18), and received ethics approval from the Research Ethics Board at the
125 University of Toronto.

126

127 **Results**

128

129 We included 212,332 cases in our analysis, with test report dates between February 7 and June
130 27, 2021. Changes over time in incidence of infections by VOC status, and in incidence of
131 infections resulting in ICU admission, are presented in **Figure 1**. Among all reported cases, 77%
132 were infections with N501Y-positive VOC; 2.7% were classified as probable Delta infections.
133 In crude comparisons, there were significant differences between variants in probability of
134 hospitalization and ICU; individuals with N501Y-positive variants and probable Delta infection
135 were significantly younger and less likely to have comorbidities than individuals with non-VOC
136 infections; N501Y-positive infections were significantly more common in the Greater Toronto
137 and Hamilton area (GTHA, the province’s largest metropolitan area); Delta variant infections

138 were significantly less common in Ottawa (the province's second largest metropolitan area)
139 (**Table 1**).

140

141 After adjustment for age, sex, vaccination status, comorbidities, health unit, and temporal trend,
142 large and significant increases in the risk of hospitalization, ICU admission, and death were seen
143 with both N501Y-positive VOC, and probable Delta infections, relative to non-VOC (**Table 2**).

144 Adjusted risks of hospitalization, ICU admission and death were 52% (43-62%), 89% (67-116%)
145 and 51% (30-74%) higher with N501Y-positive VOC than with non-VOC; respective differences
146 between non-VOC and Delta infections were 108% (80-138%), 234% (164-331%), and 132%
147 (47-230%). We identified a linear increase in severity with progression from non-VOC

148 infections to N501Y-positive infections, to Delta variant infections, with relative increases in risk
149 of hospitalization, ICU admission and death of 49% (41-58%), 86% (68-109%) and 51% (32-
150 72%), respectively (**Table 3**).

151

152 **Discussion**

153 The emergence of novel SARS-CoV-2 variants of concern has slowed progress against the
154 pandemic in three distinct ways: (i) by increasing transmissibility and the disease's reproduction
155 number; (ii) by increasing immune escape and diminishing vaccine effectiveness; and (iii) by
156 increasing the virulence of SARS-CoV-2 infection. Credible reports of enhanced virulence of
157 VOC with the N501Y mutation have emerged over the past several months (7-9), but to our
158 knowledge this is one of the first analyses to demonstrate enhanced virulence of the Delta variant
159 (10).

160

161 We show that in the Canadian province of Ontario, VOCs with the N501Y mutation were
162 associated with a markedly increased risk of hospitalization, intensive care unit admission and
163 death among infected individuals, but that the Delta variant, which is now supplanting these
164 other VOCs in Ontario, has increased these risks even further. Individuals infected with VOCs
165 were, on average, younger and less likely to have comorbid conditions than those infected with
166 non-VOC, but nonetheless had higher crude risks of hospitalization and ICU admission. Once
167 we adjusted for confounding factors such as age, vaccination status, comorbidity, and temporal
168 trends, elevated per-infection risk, including risk of death, remained markedly higher with
169 VOCs, and with Delta in particular. Indeed, given the relatively small number of Delta
170 infections in our time series, it is remarkable that a clear and significant elevation of risk of even
171 uncommon, delayed outcomes, such as death, is readily visible in our analysis.

172

173 Canada is now one of the most widely vaccinated countries in the world with respect to SARS-
174 CoV-2, and vaccination has undoubtedly blunted the impact of emergence of these VOCs. We

175 find a marked reduction in risk of severe disease and death among both partially and fully
176 vaccinated individuals in our study, consistent with the findings of Nasreen and colleagues (19).
177 Notably, our analysis is performed in a case-only dataset, so the effects we report here
178 (approximately 80-90% protection against death), represent a substantial degree of protection
179 conferred by vaccines even when they fail to prevent infection. Such direct protective effects
180 may help reduce the health impacts of ongoing SARS-CoV-2 transmission in Ontario, even if
181 herd immunity proves elusive due to the high reproduction numbers of VOC (5, 6).

182
183 Even after adjustment for vaccination status we observed downward temporal trends in case
184 severity, with a week-on-week reduced risk of hospitalization, ICU admission and death of
185 approximately 0.5% (0-1.2%), 1.9% (0.8-3.1%) and 3.9% (2.5% to 5.4%), respectively. We
186 suspect this decrease may represent attenuation of illness by vaccination in individuals who
187 would not have been considered partly or fully vaccinated using our definitions, due to
188 inadequate time elapsed since vaccination. This decrease may also represent residual
189 confounding by changing age distribution of cases over time, perhaps not captured by our broad
190 10-year age categories, due to early prioritization of older individuals for vaccination in the
191 province of Ontario (20).

192
193 An important limitation in our analysis is the possibility of our having misclassified early Delta
194 variant infections as non-VOC due to the absence of routine screening for characteristic Delta
195 mutations, with likely underestimation of the prevalence of Delta prior to May 2021. We caution
196 that such misclassification may have biased our estimates of severity downwards, and our
197 estimates of excess risk for Delta are likely biased towards the null.

198

199 In summary, we demonstrate that in the Canadian province of Ontario, despite widespread
200 vaccination and VOC infections occurring more frequently in younger and healthier individuals,
201 VOCs are associated with a substantial increase in virulence, including increased risk of death.
202 The Delta variant is more virulent than previously dominant N501Y-positive VOCs. Combined
203 with increased transmissibility and immune escape, these VOCs represent a significant escalation
204 in risk to public health during the SARS-CoV-2 pandemic.

205

206 **Acknowledgements**

207 The authors wish to thank the staff at Public Health Ontario and Ontario's public health units for
208 collecting, sequencing, analyzing, and providing access to the data used for this analysis.

Table 1. Characteristics of study cohort by variant of concern (VOC) status.

Descriptor	All	VOC Not Detected	N501Y+ VOC	Probable Delta VOC	P-value
Total Cases	212,332	43,420	162,923	5,989	
Hospitalized (%)	11,041 (5.2)	1,916 (4.4)	8,776 (5.4)	349(5.8)	<0.001
Admitted to ICU	2,325 (1.1)	338 (0.8)	1,897 (1.2)	90 (1.5)	< 0.001
Died	1821 (0.9)	385 (0.9)	1,396 (0.9)	40 (0.7)	0.23
Male (%)	107,583 (50.7)	22,023 (50.7)	82,506 (50.6)	3,054 (51.0)	0.84
Under 60 years	182,030 (85.7)	36,441 (83.9)	140,338 (86.1)	5251 (87.7)	< 0.001
Vaccination status					
Partially vaccinated	72,841 (34.3)	16,930 (39.0)	54,211(33.3)	1,700 (28.4)	< 0.001
Fully vaccinated	945 (0.4)	142 (0.3)	732 (0.4)	71 (1.2)	< 0.001
Comorbidity*	10,805 (5.1)	2,940 (6.8)	7,547 (4.6)	318 (5.3)	< 0.001
Pregnancy	555 (0.3)	124 (0.3)	410 (0.2)	21 (0.4)	0.18
Geography					
GTHA†	156,809 (73.9)	27,537 (63.4)	125,383 (77.0)	3,889 (64.9)	<0.001
Ottawa	9,326 (4.4)	1,875 (4.3)	7,334 (4.5)	117 (2.0)	<0.001

NOTE: P-values based on chi-squared test.

*Comorbidities include one or more of asthma, COPD, hematological disease, liver disease, cardiac disease, diabetes, immune compromise, renal disease, neurological disease, malignancy, or obesity.

†GTHA, Greater Toronto Area and Hamilton, large conurbation in Central Ontario consisting of 6 health units (Toronto, Peel, Durham, Halton, York and Hamilton).

Table 2. Adjusted odds ratios for hospitalization, ICU admission, and death among reported COVID-19 cases.

Covariate	Hospitalization		ICU Admission		Death	
	OR	95% CI	OR	95% CI	OR	95% CI
VOC status						
Probable Delta variant	2.08	(1.80 to 2.38)	3.34	(2.64 to 4.31)	2.32	(1.47 to 3.30)
N501Y+ variant	1.52	(1.43 to 1.62)	1.89	(1.67 to 2.16)	1.51	(1.30 to 1.74)
Male sex	1.29	(1.24 to 1.35)	1.60	(1.46 to 1.73)	1.66	(1.48 to 1.84)
Age (per 10-year increase)	2.07	(2.05 to 2.10)	1.96	(1.91 to 2.00)	3.46	(3.31 to 3.58)
Vaccination status						
Partially vaccinated	0.42	(0.40 to 0.44)	0.28	(0.25 to 0.31)	0.09	(0.08 to 0.10)
Fully vaccinated	0.31	(0.26 to 0.43)	0.15	(0.05 to 0.28)	0.21	(0.09 to 0.32)
Comorbidity	2.76	(2.59 to 2.93)	2.58	(2.30 to 2.88)	2.40	(2.09 to 2.76)
Pregnancy	6.26	(4.48 to 8.42)	6.85	(3.51 to 1100)	---	---
Series week	0.994	(0.988 to 1.00)	0.981	(0.969 to 0.992)	0.961	(0.946 to 0.975)


Table 3. Relative increase in odds ratio for hospitalization, ICU admission and death with Delta VOC as compared to N501Y-positive VOC.

Outcome	Effect of Delta vs. N501Y+ VOC		
	OR	LCL	UCL
Hospitalization	1.49	1.41	1.58
ICU Admission	1.86	1.68	2.09
Death	1.51	1.32	1.73

Additional model covariates included: sex, age, vaccination status, comorbidity, pregnancy, series week, and health unit.

Figure 1. Trends in SARS-CoV-2 Case Occurrence and distribution of hospitalizations, ICU admission, and deaths by VOC status in Ontario, Canada.

(A) Cases of reported SARS-CoV-2 infection by test report date, presented as 7-day average for cases reported between February 7 and June 27, 2021. (B) Distribution of COVID-19 hospitalized cases, cases admitted to ICU, and deaths by VOC status, by week of test report. Cases are coloured by assigned VOC status. Prior to May 1, 2021, Delta cases were only detected by whole genome sequencing. After May 1, 2021, all screened specimens not identified as an N501Y-positive VOC or another variant were classified as probable Delta VOC infections.



References

1. Tuite AR, Fisman DN, Oduyayo A, Bobos P, Allen V, Bogoch I, et al. COVID-19 hospitalizations, ICU admissions and deaths associated with the new variants of concern. Accessed 5 Jul 2021: <https://doi.org/10.47326/ocsat.2021.02.18.1.0>. 2021.
2. Public Health Ontario. Epidemiologic summary: SARS-CoV-2 whole genome sequencing in Ontario, June 30, 2021. Accessed 5 Jul 2021: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-sars-cov2-whole-genome-sequencing-epi-summary.pdf?sc_lang=en. 2021.
3. Public Health Ontario. Epidemiologic summary: Estimating the prevalence and growth of SARS-CoV-2 variants in Ontario using mutation profiles. Accessed 5 Jul 2021: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-prevalence-growth-voc-mutation-epi-summary.pdf?sc_lang=en. 2021.
4. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. 2021;372(6538).
5. Brown KA, Joh E, Buchan SA, Daneman N, Mishra S, Patel S, et al. Inflection in prevalence of SARS-CoV-2 infections missing the N501Y mutation as a marker of rapid Delta (B.1.617.2) lineage expansion in Ontario, Canada. medRxiv. 2021:2021.06.22.21259349.
6. Brown KA, Gubbay J, Hopkins J, Patel S, Buchan SA, Daneman N, et al. Rapid Rise of S-Gene Target Failure and the UK variant B.1.1.7 among COVID-19 isolates in the Greater Toronto Area, Canada. medRxiv. 2021:2021.02.09.21251225.

7. Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. *BMJ*. 2021;373:n1412.
8. Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Michaelsen TY, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. *Lancet Infect Dis*. 2021.
9. Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. *Euro Surveill*. 2021;26(16).
10. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health S, the EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet*. 2021;397(10293):2461-2.
11. Fisman DN, Greer AL, Hillmer M, O'Brien SF, Drews SJ, Tuite AR. COVID-19 case age distribution: correction for differential testing by age. *medRxiv*. 2020:2020.09.15.20193862.
12. Stall NM, Jones A, Brown KA, Rochon PA, Costa AP. For-profit long-term care homes and the risk of COVID-19 outbreaks and resident deaths. *CMAJ*. 2020;192(33):E946-E55.
13. Fisman DN, Bogoch I, Lapointe-Shaw L, McCready J, Tuite AR. Risk factors associated with mortality among residents with coronavirus disease 2019 (COVID-19) in long-term care facilities in Ontario, Canada. *JAMA Netw Open*. 2020;3(7):e2015957.
14. Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. *Am J Epidemiol*. 1982;116(3):547-53.
15. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>. 2021.

16. Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Softw.* 2015;67(1):1-48.
17. Bolker B, Robinson D. broom.mixed: Tidying methods for mixed models. R package version 0.2.7. <https://CRAN.R-project.org/package=broom.mixed>. 2021.
18. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bull World Health Organ.* 2007;85(11):867-72.
19. Nasreen S, He S, Chung H, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against variants of concern, Canada. *medRxiv.* 2021:2021.06.28.21259420.
20. Government of Ontario. Ontario's COVID-19 vaccination plan. Available via the Internet at <https://covid-19.ontario.ca/ontarios-covid-19-vaccination-plan>. Last accessed July 13, 2021. 2021.